DOP2024000016A - Proteínas actrii y usos de las mismas - Google Patents

Proteínas actrii y usos de las mismas

Info

Publication number
DOP2024000016A
DOP2024000016A DO2024000016A DO2024000016A DOP2024000016A DO P2024000016 A DOP2024000016 A DO P2024000016A DO 2024000016 A DO2024000016 A DO 2024000016A DO 2024000016 A DO2024000016 A DO 2024000016A DO P2024000016 A DOP2024000016 A DO P2024000016A
Authority
DO
Dominican Republic
Prior art keywords
telangiectasia
risk
effective amount
therapeutically effective
patient receiving
Prior art date
Application number
DO2024000016A
Other languages
English (en)
Spanish (es)
Inventor
De Oliveira Pena Janethe
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of DOP2024000016A publication Critical patent/DOP2024000016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DO2024000016A 2021-07-19 2024-01-18 Proteínas actrii y usos de las mismas DOP2024000016A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19
PCT/US2022/037479 WO2023003815A1 (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Publications (1)

Publication Number Publication Date
DOP2024000016A true DOP2024000016A (es) 2024-06-16

Family

ID=84979535

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2024000016A DOP2024000016A (es) 2021-07-19 2024-01-18 Proteínas actrii y usos de las mismas
DO2026000113A DOP2026000113A (es) 2021-07-19 2026-04-17 Proteínas actrii y usos de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
DO2026000113A DOP2026000113A (es) 2021-07-19 2026-04-17 Proteínas actrii y usos de las mismas

Country Status (18)

Country Link
US (1) US20240327494A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526820A (cg-RX-API-DMAC7.html)
KR (1) KR20240049857A (cg-RX-API-DMAC7.html)
CN (1) CN117957014A (cg-RX-API-DMAC7.html)
AU (1) AU2022316103A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225613A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000151A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024001551A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240061A (cg-RX-API-DMAC7.html)
DO (2) DOP2024000016A (cg-RX-API-DMAC7.html)
EC (1) ECSP24012819A (cg-RX-API-DMAC7.html)
GE (1) GEP20267899B (cg-RX-API-DMAC7.html)
IL (1) IL310141A (cg-RX-API-DMAC7.html)
JO (1) JOP20240010A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000829A (cg-RX-API-DMAC7.html)
PE (1) PE20240777A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023003815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI745271B (zh) * 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
WO2016146573A1 (en) * 2015-03-13 2016-09-22 Repoceuticals Aps Melatonin for preventing and treating radiation cystitis
JP7072507B2 (ja) * 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
PL4218804T3 (pl) * 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
AU2017296040C1 (en) * 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension

Also Published As

Publication number Publication date
GEAP202416461A (en) 2024-04-25
CO2024001551A2 (es) 2024-03-07
AU2022316103A1 (en) 2024-02-08
US20240327494A1 (en) 2024-10-03
MX2024000829A (es) 2024-04-12
WO2023003815A1 (en) 2023-01-26
EP4373577A4 (en) 2025-05-14
CR20240061A (es) 2024-05-02
CN117957014A (zh) 2024-04-30
JP2024526820A (ja) 2024-07-19
CL2024000151A1 (es) 2024-08-09
DOP2026000113A (es) 2026-07-15
WO2023003815A9 (en) 2023-05-11
IL310141A (en) 2024-03-01
JOP20240010A1 (ar) 2024-01-18
ECSP24012819A (es) 2024-03-01
GEP20267899B (en) 2026-06-10
CA3225613A1 (en) 2023-01-26
KR20240049857A (ko) 2024-04-17
PE20240777A1 (es) 2024-04-17
EP4373577A1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
ECSP24012819A (es) Proteínas actrii y usos de las mismas
ECSP13012792A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
MX2022010774A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
AR058838A1 (es) Metodo para tratar el dano articular
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112014021653A2 (pt) Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22
PE20212158A1 (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
AR087094A1 (es) Formulaciones que estabilizan proteinas
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
BR112022004941A2 (pt) Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
AR115883A1 (es) Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
AR104721A1 (es) Fragmento fab anti-ngf humano
DOP2025000170A (es) Proteínas de fusión fc de il-12
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
CU20160194A7 (es) Composición vacunal que comprende un mutante de la interleucina-15 humana
AR120453A1 (es) Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer